FDA Approves Trutakna for IgA Nephropathy, First Dual BAFF/APRIL Therapy to Reduce Proteinuria
First therapy to target two key immune pathways shown to reduce proteinuria
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Trutakna (atacicept-vymj) for the treatment of adults with primary immunoglobulin A (IgA) nephropathy who are at risk for disease progression.
Developed by Vera Therapeutics, Trutakna is administered as a once-weekly subcutaneous injection and is the first FDA-approved therapy to simultaneously target two immune signaling proteins, B cell activating factor (BAFF) and A Proliferation Inducing Ligand (APRIL), that contribute to the disease.
Understanding IgA Nephropathy
IgA nephropathy is a chronic kidney disease in which an abnormal form of the immunoglobulin A (IgA) antibody accumulates in the kidneys, triggering inflammation and progressive damage.
Over time, the condition can cause protein leakage into the urine (proteinuria), declining kidney function, chronic kidney disease, and kidney failure requiring dialysis or transplantation.
Reducing proteinuria is considered an important indicator of slowing disease progression and preserving kidney function.
Clinical Trial Results
FDA based its approval on a randomized, double-blind, placebo-controlled Phase 3 clinical trial involving adults with biopsy-confirmed IgA nephropathy.
After nine months of treatment, patients receiving Trutakna experienced a 46% average reduction in proteinuria when compared with patients receiving placebo.
The approval was based on improvement in this surrogate endpoint rather than direct evidence of long-term preservation of kidney function.
Novel Mechanism of Action
Trutakna is the first approved therapy designed to inhibit both BAFF and APRIL, two proteins that promote the survival and maturation of immune cells responsible for producing the abnormal IgA antibodies associated with the disease.
By reducing production of these abnormal antibodies, the therapy aims to decrease kidney inflammation and protein leakage.
Safety Considerations
Because Trutakna suppresses parts of the immune system, patients may face an increased risk of infection.
FDA recommends that healthcare providers screen patients for active infections before treatment, monitor for infections during therapy, and avoid administration of live vaccines within 30 days before starting treatment and throughout therapy.
Accelerated Approval
The approval was granted through FDA’s Accelerated Approval Program, which allows earlier access to promising therapies based on surrogate endpoints reasonably likely to predict clinical benefit.
An ongoing confirmatory clinical trial must demonstrate that Trutakna slows the long-term decline of kidney function. Continued FDA approval will depend on verification of that clinical benefit.
The application also received priority review and breakthrough therapy designation, reflecting FDA’s recognition of the unmet medical need for patients with IgA nephropathy.
Why It Matters
IgA nephropathy is one of the leading causes of chronic kidney disease worldwide and has historically had limited treatment options beyond blood pressure control and supportive care.
Trutakna introduces a new, targeted immunologic approach by addressing two key drivers of the disease rather than simply managing its complications.
Although additional data are needed to confirm long-term protection of kidney function, the approval offers a promising new option for patients at risk of progressive kidney damage and highlights the continued growth of precision therapies for immune-mediated diseases.
Regulatory Insight: Surrogate Endpoints and Accelerated Approval
When “Better” Doesn’t Yet Mean “Longer”
One of the most misunderstood aspects of FDA drug regulation is the difference between a surrogate endpoint and a clinical outcome.
Trutakna was approved because it significantly reduced proteinuria, the amount of protein leaking into the urine. Proteinuria is widely recognized as a marker associated with kidney damage and disease progression.
What has not yet been conclusively demonstrated is whether reducing proteinuria ultimately slows the long-term decline of kidney function or delays kidney failure.
FDA’s Accelerated Approval pathway allows therapies for serious diseases to reach patients earlier when improvements in a validated or reasonably likely surrogate endpoint are expected to predict clinical benefit.
The tradeoff is that manufacturers must complete post-approval confirmatory studies. If those studies fail to verify the expected benefit, FDA has the authority to modify or withdraw the approval.
Regulatory Lesson: Accelerated approval reflects confidence in promising scientific evidence, but it is not the end of the regulatory process. Continued approval depends on confirming that patients ultimately experience meaningful clinical benefit.
FDA Early Alert for Baxter Intravascular Administration Sets
Healthcare facilities are instructed to immediately stop using affected IV solution sets while FDA evaluates the potentially high-risk device issueThe U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding certain Baxter Duo-Vent Solution Sets...
Class I Recall for Bolton Medical RelayPro Thoracic Stent Graft
FDA Issues Class I Recall for RelayPro Thoracic Stent Graft Following Three Patient DeathsDeployment failure during aortic repair may require emergency open surgery The U.S. Food and Drug Administration (FDA) has issued a Class I recall for certain RelayPro Thoracic...
FDA Issues Early Alert for Resmed Astral Ventilators
Resmed VentilatorPatients should continue using devices unless instructed otherwise by their healthcare provider The U.S. Food and Drug Administration (FDA) has issued an Early Alert regarding a potentially high-risk issue affecting certain Resmed Astral 100 and...
One Contaminated Alcohol Pad, Multiple Recalls
A Lesson in Medical Device Supply Chain Quality At first glance, Cardinal Health's recent recall of Webcol™ Alcohol Prep Pads appears straightforward. A commonly used healthcare product was found to be contaminated with Paenibacillus phoenicis, creating a potential...
Early Alert: Windstone Medical Recall for Convenience Kits
FDA Warns of Convenience Kits Containing Recalled Cardinal Health Alcohol Pads The FDA has issued an Early Alert regarding several medical convenience kits distributed by Windstone Medical Packaging, Inc. that contain alcohol prep pads previously recalled by Cardinal...
Webcol Alcohol Prep Pads Recall Due to Microbial Contamination
Cardinal Health Recalls Alcohol Prep Pads Over Infection Risk Concerns Cardinal Health has issued a voluntary nationwide recall of select lots of its Webcol™ Large Alcohol Prep Pads (70% isopropyl alcohol) after testing identified microbial contamination with...
